Given Imaging: A Capsule View of GI Diagnostics' Future

Despite all of the recent advances in diagnostic imaging, the small bowel remains a black box with physicians still unable to directly view the roughly 20-foot length of this portion of the gastrointestinal tract. Small bowel direct imaging is currently limited to the first few feet through a traumatic procedure called push enteroscopy. The result of the small bowel's diagnostic inaccessibility is that many patients with conditions that arise in the small intestines are forced to undergo numerous invasive tests of other parts of the GI tract, none of which may produce conclusive results. Given Imaging has taken a futuristic approach to GI imaging by utilizing advances in a number of disparate fields, including visualization, miniaturization, and chip construction, combined with principles taken from Israeli missile design technology. The company has developed an ingestible, grape-sized capsule that transmits direct images of the entire GI tract--including for the first time the small bowel--as the device travels through and eventually is expelled from the body in a procedure called capsule endoscopy. All this while the patient goes about his or her normal daily routine. Capsule endoscopy represents the first major breakthrough in gastrointestinal diagnostic imaging in nearly 25 years. Given has been on the fast track. Less than four years from its founding, the company has obtained product approvals and done a successful IPO. But its biggest challenge remains: to overcome the inertia from the lack of innovation in GI medicine and convince gastroenterologists to adopt this radical new diagnostic tool.

by Stephen Levin

What does the science fiction movie classic, "Fantastic Voyage," with its visually spectacular miniaturized journey through the human body, have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics

 
• By 

By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

CellProthera Targeting Heart Regeneration Where No Treatment Exists

 
• By 

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion

 
• By 

Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.

More from In Vivo

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

Deals In Depth: October 2025

 
• By 

Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.

Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines

 
• By 

In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.